Potential For Functional Cure Opens Up With GSK’s Hepatitis B Candidate

Durability Test Remains

Bepirovirsen made the hepatitis B virus undetectable in nearly 30% of patients in a Phase II study – but it remains to be seen whether this response be sustained once treatment with the novel antisense product ends.

#EASL — Hepatitis B was a big focus at this year's International Liver Congress, hosted by European Association for the Study of the Liver (EASL) in London • Source: Steve Forrest & Andrew McConnell / EASL

GSK has unveiled promising interim Phase IIb results of hepatitis B candidate, bepirovirsen, which could put it on the path to providing a functional cure for more chronic patients.

The antisense oligonucleotide therapy rendered the virus undetectable in the blood of nearly 30% of patients on the B-Clear study after 24 weeks of treatment, regardless of whether it was used as a monotherapy or in combination with

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Quick Listen: Scrip’s Five Must-Know Things

19 May 2025

• By Ian Haydock

In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

16 May 2025

• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

16 May 2025

• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Regeneron Wins PCSK9 Court Battle Against Amgen

16 May 2025

• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

16 May 2025

• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.